200 related articles for article (PubMed ID: 25526234)
1. Considerations regarding adherence of anti-osteoporosis therapy.
Lagari VS; McAninch E; Baim S
Postgrad Med; 2015 Jan; 127(1):92-8. PubMed ID: 25526234
[TBL] [Abstract][Full Text] [Related]
2. Treatment of osteoporosis in women intolerant of oral bisphosphonates.
Aspray TJ; Francis RM
Maturitas; 2012 Jan; 71(1):76-8. PubMed ID: 22079368
[TBL] [Abstract][Full Text] [Related]
3. Persistence with bisphosphonate treatment for osteoporosis: finding the root of the problem.
Cramer JA; Silverman S
Am J Med; 2006 Apr; 119(4 Suppl 1):S12-7. PubMed ID: 16563936
[TBL] [Abstract][Full Text] [Related]
4. Patient treatment preferences for osteoporosis.
Fraenkel L; Gulanski B; Wittink D
Arthritis Rheum; 2006 Oct; 55(5):729-35. PubMed ID: 17013870
[TBL] [Abstract][Full Text] [Related]
5. Improving compliance and persistence with bisphosphonate therapy for osteoporosis.
Emkey RD; Ettinger M
Am J Med; 2006 Apr; 119(4 Suppl 1):S18-24. PubMed ID: 16563937
[TBL] [Abstract][Full Text] [Related]
6. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
Woodis CB
Ann Pharmacother; 2008 Jul; 42(7):1085-9. PubMed ID: 18505912
[TBL] [Abstract][Full Text] [Related]
7. Maximizing effectiveness of bisphosphonate therapy for osteoporosis.
Martens MG; Shaw H
South Med J; 2008 Aug; 101(8):824-30. PubMed ID: 18622322
[TBL] [Abstract][Full Text] [Related]
8. How can osteoporosis patients benefit more from their therapy? Adherence issues with bisphosphonate therapy.
Gold DT; Alexander IM; Ettinger MP
Ann Pharmacother; 2006 Jun; 40(6):1143-50. PubMed ID: 16735667
[TBL] [Abstract][Full Text] [Related]
9. [Intermittent long-term administration of intravenous bisphosphonates for treatment of osteoporosis].
Miyakoshi N
Clin Calcium; 2014 Jan; 24(1):93-9. PubMed ID: 24369285
[TBL] [Abstract][Full Text] [Related]
10. Physicians' perspectives on the treatment of osteoporosis patients with bisphosphonates.
Gu T; Eisenberg Lawrence DF; Stephenson JJ; Yu J
Clin Interv Aging; 2016; 11():1-8. PubMed ID: 26929609
[TBL] [Abstract][Full Text] [Related]
11. The impact of osteoporosis medication beliefs and side-effect experiences on non-adherence to oral bisphosphonates.
McHorney CA; Schousboe JT; Cline RR; Weiss TW
Curr Med Res Opin; 2007 Dec; 23(12):3137-52. PubMed ID: 17988435
[TBL] [Abstract][Full Text] [Related]
12. [Bisphosphonate].
Hagino H
Nihon Rinsho; 2015 Oct; 73(10):1683-9. PubMed ID: 26529930
[TBL] [Abstract][Full Text] [Related]
13. [Innovation of bisphosphonates for improvement of adherence.].
Takeuchi Y
Clin Calcium; 2017; 27(2):197-202. PubMed ID: 28123121
[TBL] [Abstract][Full Text] [Related]
14. Clinical strategies to address patients' concerns in osteoporosis management with bisphosphonates.
Cole RE
Postgrad Med; 2011 Mar; 123(2):131-44. PubMed ID: 21474901
[TBL] [Abstract][Full Text] [Related]
15. Effect of adherence on lifetime fractures in osteoporotic women treated with daily and weekly bisphosphonates.
Danese MD; Badamgarav E; Bauer DC
J Bone Miner Res; 2009 Nov; 24(11):1819-26. PubMed ID: 19419313
[TBL] [Abstract][Full Text] [Related]
16. Clinical evaluation of novel bisphosphonate dosing regimens in osteoporosis: the role of comparative studies and implications for future studies.
Cosman F; Borges JL; Curiel MD
Clin Ther; 2007 Jun; 29(6):1116-27. PubMed ID: 17692726
[TBL] [Abstract][Full Text] [Related]
17. [InoPro trial: collaboration between urologists and primary care physicians in the treatment of osteoporosis in prostate cancer patients].
Laufer M; Keller T; Gershman V; Ferman Z; Sarid M; Leibovitch I
Harefuah; 2014; 153(3-4):151-4, 240. PubMed ID: 24791553
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: implications of improved persistence with less frequently administered oral bisphosphonates.
Earnshaw SR; Graham CN; Ettinger B; Amonkar MM; Lynch NO; Middelhoven H
Curr Med Res Opin; 2007 Oct; 23(10):2517-29. PubMed ID: 17825128
[TBL] [Abstract][Full Text] [Related]
19. Advances in the management of corticosteroid-induced osteoporosis with bisphosphonates.
Ringe JD; Farahmand P
Clin Rheumatol; 2007 Apr; 26(4):474-84. PubMed ID: 17122953
[TBL] [Abstract][Full Text] [Related]
20. [Once-weekly teriparatide treatment on osteoporosis].
Nakano T
Clin Calcium; 2014 Jan; 24(1):100-5. PubMed ID: 24369286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
